Summary:
A phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of bimekizumab in subjects with activate ankylosing spondylitis.
Qualified Participants Must:
• Subject is male or female at least 18 years of age
• Including documented radiologic evidence
• Inflammatory back pain for at least 3 months prior to screening visit
• Age at symptoms onset prior to age 45
• Subjects must have at least 1 of the following: Inadequate responce to nsaids therapy, or intolerance to administrationof at least 1 nsaid, or contraindiction to nsaid therapy
Qualified Participants May Receive:
Subjects that qualify and are enrolled into the study will receive the following: doctor evaluation, blood work results, $40.00 per visit completed.